← Leaderboards
Donald Lo
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Toxicology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- David Heimbrook · Leidos Biomedical Research, Inc.$155,080,196
- Barney Sparrow · Battelle Memorial Institute$96,886,832
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Robert H Vonderheide · University Of Pennsylvania$78,967,264
- Reshan Fernando · Research Triangle Institute$70,521,464
Research focus
ToxicologyLeadPharmaceutical PreparationsFormulationDrug KineticsInvestigational DrugsCollaborationsClinical TrialsAdme StudyBaseResearch Clinical TestingResearch PersonnelSignal TransductionDesignCellsAnimal ModelScientistGenesSafetyBiological AvailabilityBindingUnited States National Institutes Of HealthPlayPre-Clinical Model
Grant awards (36)
Helping to End Addiction Long-term (HEAL): Development of Clinical Candidate Drugs for Pain, Addiction and Overdose$10,316,802
ZIA · FY2022 · TR · contact PI
Gene Therapy Platform for Rare Diseases$6,246,466
ZIA · FY2022 · TR · contact PI
Development of Nogo Receptor Decoy for the Treatment of Spinal Cord Injury$5,800,456
ZIA · FY2022 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer$1,546,525
ZIA · FY2022 · TR · contact PI
Antisense Oligonucleotide (ASO) Development for Rare and Neglected Diseases$1,450,000
ZIA · FY2022 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$1,306,225
ZIA · FY2022 · TR · contact PI
Short Stabilized EPO-Peptide as Therapeutic Agents for Multiple Sclerosis and Acute Brain Trauma$1,306,225
ZIA · FY2022 · TR · contact PI
IND-Enabling Pre-Clinical Studies of 2DG for Treatment of Epilepsy$1,306,224
ZIA · FY2022 · TR · contact PI
Development of Drinabant for Treatment of Acute Cannabinoid Overdose$1,200,250
ZIA · FY2022 · TR · contact PI
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers$853,006
ZIA · FY2022 · TR · contact PI
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2$775,431
ZIA · FY2022 · TR · contact PI
Helping to End Addiction Long-term (HEAL): Development of Clinical Candidate Drugs for Pain, Addiction and Overdose$9,556,745
ZIA · FY2021 · TR · contact PI
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2$3,643,319
ZIA · FY2021 · TR · contact PI
Gene Therapy Platform for Rare Diseases$3,308,335
ZIA · FY2021 · TR · contact PI
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2$1,352,770
ZIA · FY2021 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$1,215,243
ZIA · FY2021 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer$1,104,680
ZIA · FY2021 · TR · contact PI
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers$1,071,030
ZIA · FY2021 · TR · contact PI
HEAL: Development of Clinical Candidate Drugs for Pain, Addiction and Overdose$10,299,226
ZIA · FY2020 · TR · contact PI
Gene Therapy Platform for Rare Diseases$5,164,330
ZIA · FY2020 · TR · contact PI
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2$1,991,523
ZIA · FY2020 · TR · contact PI
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers$502,769
ZIA · FY2020 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer$340,226
ZIA · FY2020 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$258,356
ZIA · FY2020 · TR · contact PI
HEAL: Development of Clinical Candidate Drugs for Pain, Addiction and Overdose$9,587,227
ZIA · FY2019 · TR · contact PI
BPN14770 For Treatment of Fragile X Syndrome$584,966
ZIA · FY2019 · TR · contact PI
Metarrestin for the Treatment of Pancreatic Cancer$543,703
ZIA · FY2019 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer$185,600
ZIA · FY2019 · TR · contact PI
Peripheral CB1 Receptor Antagonist for Therapeutic Use in Metabolic Syndrome$168,523
ZIA · FY2019 · TR · contact PI
Development of an ApoA-1 Mimetic Peptide for Treatment of Atherosclerosis$156,330
ZIA · FY2019 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$152,333
ZIA · FY2019 · TR · contact PI
Metarrestin for the Treatment of Pancreatic Cancer$448,357
ZIA · FY2018 · TR · contact PI
Peripheral CB1 Receptor Antagonist for Therapeutic Use in Metabolic Syndrome$116,170
ZIA · FY2018 · TR · contact PI
Development of an ApoA-1 Mimetic Peptide for Treatment of Atherosclerosis$87,278
ZIA · FY2018 · TR · contact PI
Evaluation of ACT1 to Treat Diabetic Keratopathy$76,841
ZIA · FY2018 · TR · contact PI
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer$41,000
ZIA · FY2018 · TR · contact PI